Latest Comparison,Results of the FOCUS trial are expected in 2026

The FOCUS trial is a pivotal research initiative investigating the impact of semaglutide on diabetic retinopathy (DR), a serious complication of diabetes that can lead to vision loss. As 2025 approaches, with results from this significant trial eagerly anticipated, understanding the current landscape of research surrounding semaglutide and diabetic retinopathy is crucial for patients and healthcare professionals alike.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated considerable success in managing type 2 diabetes and promoting weight loss. However, its precise effect on diabetic retinopathy has been a subject of ongoing investigation, with some studies suggesting potential benefits and others raising concerns about early worsening. The FOCUS trial, a randomized, double-masked, parallel-group, placebo-controlled study, aims to provide definitive answers. Initiated in 2019 and involving 176 clinical sites, the FOCUS trial is expected to be completed in 2027, with preliminary results anticipated around 2025 and a more comprehensive understanding of the FOCUS trial results expected in 2026.

Current research offers a nuanced picture. A systematic review including 12 randomized controlled trials (RCTs) identified the efficacy and tolerability of semaglutide compared to placebo or other antidiabetic medications. While semaglutide is generally considered well-tolerated, some findings have indicated a potential for early worsening of diabetic retinopathy. For instance, the SUSTAIN 6 cardiovascular outcome trial of semaglutide reported diabetic retinopathy endpoints in a significantly higher number of individuals randomized to semaglutide. This has led to recommendations for retinopathy screening before initiating semaglutide treatment, pending definitive results from the FOCUS trial.

Conversely, other analyses suggest that semaglutide use may not be linked to an increased risk of diabetic retinopathy. A meta-analysis indicated no heightened risk for diabetic retinopathy, although a small increased risk for NAION (non-arteritic anterior ischemic optic neuropathy) was observed. Another database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy. These seemingly contradictory findings highlight the complexity of semaglutide's impact on retinal health and underscore the importance of the FOCUS trial.

The FOCUS Trial is designed to specifically address these questions by evaluating the effects of semaglutide versus placebo on diabetic retinopathy. The study will look at the long-term effects of semaglutide on diabetic eye disease when compared to a placebo. Early indications from some observational studies suggest that semaglutide may not worsen diabetic retinopathy, with only a small percentage of eyes experiencing worsening after two years of treatment. Furthermore, some research posits that GLP-1 receptor agonists can enhance retinal cells' defenses against damage in diabetes-like conditions, suggesting a potential protective role.

The ongoing OHDSI network study, analyzing data from a large cohort of new semaglutide users with type 2 diabetes, found the risk of proliferative diabetic retinopathy to be similar to that of dulaglutide. However, this study also noted that the current literature reveals semaglutide has an uncertain effect on diabetic retinopathy progression, emphasizing the need for larger, randomized clinical trials.

As the FOCUS trial progresses, its results are expected to significantly influence clinical practice concerning the use of semaglutide in patients with diabetes. The anticipation for these results is high, particularly given the increasing prevalence of diabetes and its associated complications. Understanding the precise relationship between semaglutide and diabetic retinopathy will be crucial for optimizing treatment strategies and preserving vision for millions worldwide. The ongoing research into semaglutide's role in diabetic eye disease is a testament to the continuous effort to improve diabetes care and mitigate its long-term consequences. The semaglutide's potential dual role in DR, particularly its potential to mitigate retinal vascular and other damage, warrants further investigation, which the FOCUS trial is poised to deliver.